Madele MvD van Dyk
Dr van Dyk is a motivated Early Career Research Fellow, currently funded by the Cancer Council SA working within the area of Precision Dosing at Basil Hetzel Institute, Queen Elizabeth Hospital in collaboration with leading cancer research centres interstate and internationally. Dr van Dyk is interested in overcoming the challenges that we face with newer anticancer therapies where therapeutic failure and toxicity is responsible for poor patient outcome. Therefore, she has a strong focus in the optimisation and individualisation of treatment in cancer patients in real time. She has a background in developing and validating analytical chemistry-based methods for the quantification of cancer drugs for both research and clinical purposes, to aid therapeutic drug monitoring. This has led to an initiation of a state-wide Clinical Program available to all oncologists and haematologists in Australia. She is also interested in running research-based clinical studies in patients on already approved medications to investigate how we could improve the quality of such routinely used cancer drugs. Dr van Dyk also researchers several other strategies such as model-informed precision dosing and phenotyping studies to further optimise dosing with cancer drugs. She enjoys sharing research ideas and collaborate with driven consumers, scientists or clinicians to further improve cancer research in Australia. She attributes her strong relationships with cancer patients that led to successful translation of the clinical program.
Abstracts this author is presenting: